Market Place
Sourcing Support
Chugai`s Alecensa Approved In Japan For Early-Stage ALK+ NSCLC
29 Aug 2024 //
PHARMABIZ
Taiwan FDA Approves Chugai`s Alecensa For Early Stage ALK+ NSCLC
03 Aug 2024 //
PHARMABIZ
FDA Issues form 483 to Chugai Pharma Manufacturing
14 Jun 2024 //
FDA
Helsinn & Chugai sign a partnership agreement renewal to commercialize AKYNZEO
12 Jun 2024 //
GLOBENEWSWIRE
Chugai in-licenses RNAi therapeutic zilebesiran for hyp.high cardiovascular risk
20 Apr 2024 //
PHARMABIZ
Chugai Pharma announces Japanese phase III study of Vabysmo
16 Apr 2024 //
PHARMABIZ
Chugai: Piasky (crovalimab) for Paroxysmal Nocturnal Hemoglobinuria approved in Japan
26 Mar 2024 //
PRESS RELEASE
Roche autoimmune disease drug disappoints in closely watched trial
22 Mar 2024 //
BIOPHARMADIVE
Chugai’s Paroxysmal nocturnal hemoglobinuria drug bags first approval in China
13 Feb 2024 //
BIOSPECTRUM ASIA
Chugai seeks Japanese approval for crovalimab to treat PNH
15 Jun 2023 //
PHARMABIZ
Chugai obtains Japanese approval for FoundationOne Liquid CDx Genomic Profile
27 May 2023 //
PHARMABIZ
Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Care
02 Mar 2023 //
PR NEWSWIRE
Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication
24 Dec 2022 //
PHARMABIZ
Chugai Pharma & Towa Pharma introduce Edirol tablet for osteoporosis treatment
10 Dec 2022 //
PHARMABIZ
Chugai Pharma completes its new research centre, Chugai LSP Yokohama
19 Oct 2022 //
PHARMABIZ
Japan approves Chugai Pharma`s osteoporosis drug
16 Aug 2022 //
BIOSPECTRUMASIA
Chugai Gets Priority Review for PNH Med Crovalimab in China
09 Aug 2022 //
PRESS RELEASE
Notice of the Settlement of Patent Infringement Litigation in the U.S.
08 Aug 2022 //
PRESS RELEASE
Chugai, Halozyme Therapeutics partner for ENHANZE Technology
04 Apr 2022 //
BIOSPECTRUMASIA
Chugai gets Japanese approval for Perjeta, Herceptin in HER-2 positive CC
29 Mar 2022 //
PHARMABIZ
Maruho gets Japanese approval for Mitchga to treat Itching in atopic dermatitis
29 Mar 2022 //
PHARMABIZ
Halozyme, Chugai Enter Collaboration & License Agreement for ENHANZE Technology
24 Mar 2022 //
PRNEWSWIRE
Roche, AstraZeneca settle Ultomiris patent lawsuit
19 Feb 2022 //
FIERCEPHARMA
Roche Unit, AstraZeneca’s Alexion Settle Ultomiris Patent Suit
16 Feb 2022 //
BLOOMBERGLAW
Chugai’s Actemra gets MHLW approval for addn. indication of SARS-CoV-2 pneumonia
22 Jan 2022 //
PHARMABIZ
Zenyaku Kogyo gets Japanese approval for anti-CD20 mAb, Rituxan
24 Dec 2021 //
PHARMABIZ
China introduces whole course management system for osteoporosis patients
22 Dec 2021 //
BIOSPECTRUMASIA
Chugai obtains excl. marketing rights in Japan for delandistrogene in DMD
17 Dec 2021 //
PHARMABIZ
Chugai Pharma to discontinue development of oral Covid-19 drug, AT-527 in Japan
17 Dec 2021 //
PHARMABIZ
Chugai In-Licenses Gene Therapy Delandistrogene Moxeparvovec (SRP-9001)
16 Dec 2021 //
Chugai seeks Japanese approval for additional indication of Polivy for DLBCL
10 Dec 2021 //
PHARMABIZ
Chugai’s Herceptin gets Japanese approval for salivary gland cancer
26 Nov 2021 //
PHARMABIZ
Chugai hosts discussion series in partnership with C/Can
17 Nov 2021 //
PHARMABIZ
Chugai Files for Additional Indication of Hemlibra for Acquired Hemophilia A
11 Nov 2021 //
FIRSTWORDPHARMA
Japan stocks end lower as dour earnings hit construction firms
07 Nov 2021 //
REUTERS
Completion of Enrollment in Phase III Comparative Study for (gMSC®1)
27 Oct 2021 //
PRESS RELEASE
111, Chugai Pharma Partner to Aid Innovations in Chronic Disease Management
25 Oct 2021 //
PRNEWSWIRE
Chugai, Oncolys BioPharma to terminate exclusive license agreement on OBP-301
20 Oct 2021 //
PHARMABIZ
Chugai Files for Additional Indications of Antibody Cocktail Ronapreve
12 Oct 2021 //
PRESS RELEASE
Japan`s Chugai files to expand use of COVID-19 antibody drug
12 Oct 2021 //
REUTERS
Chugai Pharma’s Hemlibra gets Japanese ODD status for acquired hemophilia A
04 Oct 2021 //
PHARMABIZ
Zenyaku Kogyo receives Japanese nod for Rituxan in systemic sclerosis
28 Sep 2021 //
PHARMABIZ
Chugai Launches Evrysdi Dry Syrup 60 mg for the Treatment of SMA
12 Aug 2021 //
PRESS RELEASE
Chugai introduces Evrysdi dry syrup 60 mg to treat spinal muscular atrophy
12 Aug 2021 //
PHARMABIZ
Chugai introduces Evrysdi dry syrup 60 mg to treat spinal muscular atrophy
12 Aug 2021 //
PHARMABIZ
Japan`s Chugai Pharma unveils comprehensive genomic profiling test for cancer
03 Aug 2021 //
BIOSPECTRUM ASIA
Chugai introduces FoundationOne Liquid CDx Cancer Genomic Profile
02 Aug 2021 //
PHARMABIZ
Chugai obtains regulatory approval for anti-SARS-CoV-2 monoclonal antibody
20 Jul 2021 //
EXPRESS PHARMA
Chugai Pharma - Japanese approval antiSARS-CoV2 monoclonal antibody Ronapreve
20 Jul 2021 //
PHARMABIZ
Chugai inks pact with Alebund Pharma
10 Jul 2021 //
PHARMABIZ
Chugai Pharma seeks Japanese approval for Tecentriq
07 Jul 2021 //
PHARMABIZ
Chugai seeks special approval of emergency from Japan for antibody cocktail
01 Jul 2021 //
PHARMABIZ
Enspryng (satralizumab) from Chugai, approved by the European Commission
29 Jun 2021 //
BUSINESSWIRE
Japan`s Chugai applies for approval of antibody treatment for COVID-19
29 Jun 2021 //
REUTERS
Japan`s Chugai applies for approval of antibody treatment for COVID-19
29 Jun 2021 //
REUTERS
Chugai Enspryng (satralizumab), approved by the European Commission
28 Jun 2021 //
BUSINESSWIRE
Chugai Pharma’s Evrysdi receives Japanese approval
23 Jun 2021 //
PHARMABIZ
Chugai Presses on with Japan Development of 3 COVID-19 Drugs, Aims
14 May 2021 //
JIHO
Japan secures supply of investigational antibody cocktail for COVID-19 treatment
10 May 2021 //
BIOSPECTRUMASIA
Chugai Pharma & SBI Pharma to terminate license agreement for photodynamic
10 May 2021 //
PHARMABIZ
